Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target
Benzinga Newsdesk 7 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.
Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.